JP2017529382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529382A5 JP2017529382A5 JP2017516874A JP2017516874A JP2017529382A5 JP 2017529382 A5 JP2017529382 A5 JP 2017529382A5 JP 2017516874 A JP2017516874 A JP 2017516874A JP 2017516874 A JP2017516874 A JP 2017516874A JP 2017529382 A5 JP2017529382 A5 JP 2017529382A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- amino
- trifluoromethyl
- pharmaceutical composition
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 8
- 208000032612 Glial tumor Diseases 0.000 claims description 7
- 206010018338 Glioma Diseases 0.000 claims description 7
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims description 7
- 108700028369 Alleles Proteins 0.000 claims description 5
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 239000006186 oral dosage form Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 3
- URUBZXVIOILFLM-UHFFFAOYSA-N CC(C)(CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F)OS(C)(=O)=O Chemical compound CC(C)(CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F)OS(C)(=O)=O URUBZXVIOILFLM-UHFFFAOYSA-N 0.000 claims 3
- DYLUUSLLRIQKOE-UHFFFAOYSA-N enasidenib Chemical compound N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 DYLUUSLLRIQKOE-UHFFFAOYSA-N 0.000 claims 3
- 125000004317 1,3,5-triazin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=N1 0.000 claims 2
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 claims 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- SWWHCQCMVCPLEQ-UHFFFAOYSA-N propan-2-yl methanesulfonate Chemical compound CC(C)OS(C)(=O)=O SWWHCQCMVCPLEQ-UHFFFAOYSA-N 0.000 claims 2
- -1 {[2- (trifluoromethyl) pyridin-4-yl] amino} -1,3,5-triazin-2-yl Chemical group 0.000 claims 1
- 230000035772 mutation Effects 0.000 description 13
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 10
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 10
- 229940125782 compound 2 Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229940125904 compound 1 Drugs 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 208000037844 advanced solid tumor Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000001401 hemangioblastic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056996P | 2014-09-29 | 2014-09-29 | |
| US62/056,996 | 2014-09-29 | ||
| PCT/US2015/052598 WO2016053850A1 (en) | 2014-09-29 | 2015-09-28 | Therapeutically active compounds and their methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020084527A Division JP2020147571A (ja) | 2014-09-29 | 2020-05-13 | 治療活性を有する化合物及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017529382A JP2017529382A (ja) | 2017-10-05 |
| JP2017529382A5 true JP2017529382A5 (enExample) | 2018-11-01 |
Family
ID=54289133
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516874A Pending JP2017529382A (ja) | 2014-09-29 | 2015-09-28 | 治療活性を有する化合物及びその使用方法 |
| JP2020084527A Pending JP2020147571A (ja) | 2014-09-29 | 2020-05-13 | 治療活性を有する化合物及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020084527A Pending JP2020147571A (ja) | 2014-09-29 | 2020-05-13 | 治療活性を有する化合物及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9694013B2 (enExample) |
| EP (1) | EP3200800A1 (enExample) |
| JP (2) | JP2017529382A (enExample) |
| KR (1) | KR20170057411A (enExample) |
| AU (1) | AU2015324158A1 (enExample) |
| CA (1) | CA2962943A1 (enExample) |
| IL (1) | IL251246A0 (enExample) |
| WO (1) | WO2016053850A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105916507A (zh) | 2013-08-02 | 2016-08-31 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| AU2015324158A1 (en) * | 2014-09-29 | 2017-04-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3253746A1 (en) | 2015-02-04 | 2017-12-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN108349933A (zh) | 2015-08-05 | 2018-07-31 | 安吉奥斯医药品有限公司 | 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法 |
| JP2018534288A (ja) | 2015-10-15 | 2018-11-22 | アジオス ファーマシューティカルズ， インコーポレイテッド | 悪性腫瘍の治療のための併用療法 |
| CA3002029A1 (en) | 2015-10-15 | 2017-04-20 | Celgene Corporation | Combination therapy for treating malignancies |
| MA43374A (fr) | 2015-12-04 | 2018-10-10 | Agios Pharmaceuticals Inc | Méthodes de traitement de tumeurs malignes |
| CA3015753A1 (en) * | 2016-02-26 | 2017-08-31 | Celgene Corporation | Idh2 inhibitors for the treatment of haematological maligancies and solid tumours |
| WO2018010142A1 (en) * | 2016-07-14 | 2018-01-18 | Shanghai Meton Pharmaceutical Co., Ltd | Iso-citrate dehydrogenase (idh) inhibitor |
| KR102498693B1 (ko) * | 2016-09-07 | 2023-02-10 | 셀진 코포레이션 | 정제 조성물 |
| WO2018204787A1 (en) | 2017-05-05 | 2018-11-08 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| JP7306634B2 (ja) * | 2017-10-19 | 2023-07-11 | 一般社団法人ファルマバレープロジェクト支援機構 | Ｉｄｏ／ｔｄｏ阻害剤 |
| CN111670034A (zh) * | 2017-11-29 | 2020-09-15 | 洛克菲勒大学 | 用于治疗自身免疫性疾病的吡喃并吡唑类和吡唑并吡啶类免疫调节剂 |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020239759A1 (en) * | 2019-05-27 | 2020-12-03 | Sandoz Ag | Amorphous enasidenib in a stabilized form |
| US20220401450A1 (en) | 2019-11-14 | 2022-12-22 | Celgene Corporation | Pediatric formulations for treatment of cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201800334T1 (it) | 2012-01-06 | 2018-09-13 | Agios Pharmaceuticals Inc | Composti terapeuticamente attivi e loro metodi di utilizzo |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| MX375030B (es) | 2013-07-11 | 2025-03-06 | Agios Pharmaceuticals Inc | Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer. |
| CN105916507A (zh) | 2013-08-02 | 2016-08-31 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| AU2015324158A1 (en) * | 2014-09-29 | 2017-04-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3253746A1 (en) | 2015-02-04 | 2017-12-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN108349933A (zh) | 2015-08-05 | 2018-07-31 | 安吉奥斯医药品有限公司 | 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法 |
| JP2018534288A (ja) | 2015-10-15 | 2018-11-22 | アジオス ファーマシューティカルズ， インコーポレイテッド | 悪性腫瘍の治療のための併用療法 |
| MA43374A (fr) | 2015-12-04 | 2018-10-10 | Agios Pharmaceuticals Inc | Méthodes de traitement de tumeurs malignes |
| CA3015753A1 (en) | 2016-02-26 | 2017-08-31 | Celgene Corporation | Idh2 inhibitors for the treatment of haematological maligancies and solid tumours |
-
2015
- 2015-09-28 AU AU2015324158A patent/AU2015324158A1/en not_active Abandoned
- 2015-09-28 JP JP2017516874A patent/JP2017529382A/ja active Pending
- 2015-09-28 CA CA2962943A patent/CA2962943A1/en not_active Abandoned
- 2015-09-28 EP EP15778158.4A patent/EP3200800A1/en not_active Withdrawn
- 2015-09-28 US US14/868,283 patent/US9694013B2/en active Active
- 2015-09-28 KR KR1020177010757A patent/KR20170057411A/ko not_active Ceased
- 2015-09-28 WO PCT/US2015/052598 patent/WO2016053850A1/en not_active Ceased
-
2017
- 2017-03-17 IL IL251246A patent/IL251246A0/en unknown
- 2017-06-02 US US15/612,984 patent/US9889137B2/en active Active
-
2018
- 2018-01-08 US US15/864,994 patent/US10105369B2/en active Active
-
2020
- 2020-05-13 JP JP2020084527A patent/JP2020147571A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3515446B1 (en) | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor | |
| Dong et al. | New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors | |
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| US9161946B2 (en) | Dosing methods for treating disease | |
| Norden et al. | Ibuprofen ameliorates fatigue-and depressive-like behavior in tumor-bearing mice | |
| JP2016540738A5 (enExample) | ||
| JP2015528471A5 (enExample) | ||
| JP2018534311A5 (enExample) | ||
| BR112014027010A2 (pt) | uso de laquinimod de alta dose para tratamento de esclerose múltipla | |
| JP2014525454A5 (enExample) | ||
| JP2016517401A5 (enExample) | ||
| US20190290652A1 (en) | Method for treatment of solid malignancies including advanced or metastatic solid malignancies | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| KR20170098813A (ko) | 대장암 치료에 사용하기 위한 아필리모드 | |
| JP2023515765A (ja) | Ｂｉ８５３５２０と化学療法薬の併用 | |
| JP2019515909A5 (enExample) | ||
| TW202214242A (zh) | 西奧羅尼或其衍生物在製備用於預防和/或治療非霍奇金淋巴瘤的藥物之用途 | |
| JP2017128610A (ja) | 併用ａｌｓ療法 | |
| RU2014131265A (ru) | Способ обеспечения требуемых уровней фактора 2 роста глии в плазме | |
| JP2020500868A5 (enExample) | ||
| JP2023524789A5 (enExample) | ||
| JP2011513310A5 (enExample) | ||
| KR20120023754A (ko) | Ａｖｅ８０６２ 및 소라페닙을 포함하는 항종양 조합물 | |
| JP2018522049A5 (enExample) | ||
| JP2023509191A (ja) | 癌を治療するための組み合わせ療法 |